Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2015 | 2 |
2016 | 2 |
2021 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
Cancer Chemother Pharmacol. 2016 Jan;77(1):155-62. doi: 10.1007/s00280-015-2909-2. Epub 2015 Nov 14.
Cancer Chemother Pharmacol. 2016.
PMID: 26576779
Clinical Trial.
Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress.
Yao HP, Zhao H, Hudson R, Tong XM, Wang MH.
Yao HP, et al.
Drug Discov Today. 2021 Aug;26(8):1857-1874. doi: 10.1016/j.drudis.2021.06.012. Epub 2021 Jul 3.
Drug Discov Today. 2021.
PMID: 34224904
Free article.
Review.
Nevertheless, progress in duocarmycin-based ADCs also faces challenges, with setbacks including the termination of BMS-936561/MDX-1203. In this review, we discuss issues associated with the efficacy, pharmacokinetic profile, and toxicological activity of these bioth …
Nevertheless, progress in duocarmycin-based ADCs also faces challenges, with setbacks including the termination of BMS-936561/MDX- …
Item in Clipboard
Novel detection of DNA-alkylated adducts of antibody-drug conjugates with potentially unique preclinical and biomarker applications.
Thevanayagam L, Bell A, Chakraborty I, Sufi B, Gangwar S, Zang A, Rangan V, Rao C, Wang Z, Pan C, Chong C, Cardarelli P, Deshpande S, Srinivasan M.
Thevanayagam L, et al.
Bioanalysis. 2013 May;5(9):1073-81. doi: 10.4155/bio.13.57.
Bioanalysis. 2013.
PMID: 23641697
BACKGROUND: MDX-1203 is an antibody-drug conjugate (ADC) currently in clinical trials for the treatment of renal carcinoma. The active ingredient of MDX-1203 is a DNA minor groove-binding cytotoxic drug that forms a covalently linked adduct with an ade …
BACKGROUND: MDX-1203 is an antibody-drug conjugate (ADC) currently in clinical trials for the treatment of renal carcinoma. Th …
Item in Clipboard
Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans.
Wang H, Rangan VS, Sung MC, Passmore D, Kempe T, Wang X, Thevanayagam L, Pan C, Rao C, Srinivasan M, Zhang Q, Gangwar S, Deshpande S, Cardarelli P, Marathe P, Yang Z.
Wang H, et al.
Biopharm Drug Dispos. 2016 Mar;37(2):93-106. doi: 10.1002/bdd.1953. Epub 2015 May 15.
Biopharm Drug Dispos. 2016.
PMID: 25869904
Item in Clipboard
Cite
Cite